6-乙氧基-2-萘甲醛 | 757230-55-0

• 物质功能分类: 有机原料 - 醛类化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 6-乙氧基-2-萘甲醛
• 英文名称: 6-ethoxy-2-naphthaldehyde
• 英文别名: 6-ethoxynaphthalene-2-carboxaldehyde；6-ethoxynaphthalene-2-carbaldehyde
• CAS: 757230-55-0
• 化学式: C₁₃H₁₂O₂
• 分子量: 200.237
• InChiKey: OSGZDTOUNPFJEP-UHFFFAOYSA-N

物化性质

• 熔点：
  67.3-68.1 °C(Solv: methanol (67-56-1))
• 沸点：
  352.0±15.0 °C(Predicted)
• 密度：
  1.139±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  6-乙氧基-2-萘甲醛 在 N-溴代丁二酰亚胺(NBS) 、 sodium ethanolate 、 N,N-二异丙基乙胺 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 2.33h， 生成 5-amino-1-tert-butyl-3-(6-ethoxynaphthalen-2-yl)-1H-pyrazole-4-carboxamide
  参考文献：
  名称：

  [EN] 5-AMINOPYRAZOLE-4-CARBOXAMIDE INHIBITORS OF CDPK1 FROM T. GONDII AND C. PARVUM
  [FR] INHIBITEURS 5-AMINOPYRAZOLE-4-CARBOXAMIDE DE CDPK1 ISSUES DE T. GONDII ET C. PARVUM

  摘要：

  本公开通常涉及用于治疗顶复门原虫相关疾病的组合物和方法，例如弓形虫病和隐孢子虫病。

  公开号：

  WO2014189947A1
• 作为产物：
  描述：

  6-ethoxy-2-naphthalenemethanamine hydrochloride 在 bovine plasma amine oxidase 、 水 、 氧气 作用下， 生成 6-乙氧基-2-萘甲醛
  参考文献：
  名称：

  牛血浆胺氧化酶的灵敏、选择性和紧密结合的荧光底物的发现

  摘要：

  我们报告了牛血浆胺氧化酶 (BPAO) 的一种新型荧光底物，即 (2-(6-(氨基甲基)萘-2-基氧基)乙基)三甲基铵 (ANETA)，它与 ​​BPAO ( K m 183 ± 14 nM) 并且代谢相当快 ( k cat 0.690 ± 0.010 s -1），醛转换产物（2-（6-甲酰基萘-2-基氧基）乙基）三甲基铵作为酶活性的实时报告荧光团。这允许开发比分光光度法苄胺检测灵敏度高 2 个数量级的荧光非耦合检测。ANETA 的发现涉及通过基于结构的设计精心设计先导化合物 6-甲氧基-2-萘甲胺，该设计将 BPAO 的辅助阳离子结合位点视为控制结合亲和力的最重要的结构特征。基于结构的设计进一步确保了高选择性：ANETA 是 BPAO 的良好底物，但不是猪肾二胺氧化酶 (pkDAO) 或大鼠肝单胺氧化酶 (MAO-B) 的底物。ANETA 代表了第一个高度敏感、选择性、直接实时了解酶活性。

  DOI：

  10.1021/jo8018945

文献信息

• Arylthiosemicarbazones as antileishmanial agents
  作者：José Ignacio Manzano、Florent Cochet、Benjamin Boucherle、Verónica Gómez-Pérez、Ahcène Boumendjel、Francisco Gamarro、Marine Peuchmaur

  DOI：10.1016/j.ejmech.2016.07.014

  日期：2016.11

  the most active derivative (compound 14) showing an EC50 of 0.8 μM with very low toxicity on two different mammalian cell lines. The most relevant structural elements required for higher activity indicate that the presence of a fused bicyclic aromatic ring such as a naphthalene bearing an alkyl or an alkoxy group substituent are prerequisites. Owing to the easy synthesis, high activity and low toxicity

  在筛选过程的基础上，我们将取代的硫半脲靶向为潜在的抗菌药。我们的目标是确定有助于抗寄生虫活性的关键结构要素，这些要素可用于开发有效的药物。合成了一系列的32种化合物，并评估了其对利什曼原虫的临床相关细胞内酰胺的功效。从这些化合物中，有22种化合物的EC 50值低于10μM，活性最高的衍生物（化合物14）的EC 50值为50在两个不同的哺乳动物细胞系中，其毒性仅为0.8μM，毒性极低。更高活性所需的最相关的结构元素表明，存在稠合的双环芳环如带有烷基或烷氧基取代基的萘是先决条件。由于易于合成，高活性和低毒性，最具活性的化合物可被视为进一步开发的先导。
• [EN] PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS<br/>[FR] PYRAZOLO[4,3-D]PYRIMIDINES UTILES EN TANT QU'INHIBITEURS DE KINASES
  申请人：ORIGENIS GMBH

  公开号：WO2014060112A1

  公开（公告）日：2014-04-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及具有式（I）的新化合物，其能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物可用于治疗多种疾病。这些疾病包括自身免疫疾病、炎症性疾病、骨疾病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼部疾病、传染病和激素相关疾病。
• Indazole compounds and methods of use thereof
  申请人：Bhagwat S. Shripad

  公开号：US20060004043A1

  公开（公告）日：2006-01-05

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseses or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防广泛的疾病和紊乱方面具有实用性，这些疾病和紊乱对激酶的抑制、调节或调控具有反应性，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病有关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛和其他疾病。因此，本发明还揭示了治疗或预防此类疾病和紊乱的方法，以及包含一种或多种吲唑化合物的药物组成物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，它们在蛋白激酶调节方面具有强效活性。因此，本发明包括口服活性分子以及可用于治疗与蛋白激酶信号转导相关的疾病或紊乱的肠外活性分子，其剂量或血清浓度较低。
• INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Bhagwat Shripad S.

  公开号：US20090099178A1

  公开（公告）日：2009-04-16

  This invention is directed to Indazole Compounds or pharmaceutically acceptable salts, solvates and hydrates thereof. The Indazole Compounds have utility in the treatment or prevention of a wide range of diseases and disorders that are responsive to the inhibition, modulation or regulation of kinases, such as inflammatory diseases, abnormal angiogenesis and diseases related thereto, cancer, atherosclerosis, a cardiovascular disease, a renal disease, an autoimmune condition, macular degeneration, disease-related wasting, an asbestos-related condition, pulmonary hypertension, diabetes, obesity, pain and others. Thus, methods of treating or preventing such diseases and disorders are also disclosed, as are pharmaceutical compositions comprising one or more of the Indazole Compounds. This invention is based, in part, upon the discovery of a novel class of 5-triazolyl substituted indazole molecules that have potent activity with respect to the modulation of protein kinases. Thus, the invention encompasses orally active molecules as well as parenterally active molecules which can be used at lower doses or serum concentrations for treating diseases or disorders associated with protein kinase signal transduction.

  本发明涉及吲唑化合物或其药学上可接受的盐、溶剂合物和水合物。这些吲唑化合物在治疗或预防许多对激酶的抑制、调节或调控具有反应性的疾病和障碍方面具有用途，例如炎症性疾病、异常血管生成及相关疾病、癌症、动脉粥样硬化、心血管疾病、肾脏疾病、自身免疫疾病、黄斑变性、与疾病相关的消耗、石棉相关疾病、肺动脉高压、糖尿病、肥胖症、疼痛等。因此，本发明还揭示了治疗或预防这些疾病和障碍的方法，以及包含一种或多种吲唑化合物的制药组合物。本发明部分基于发现一类新型的5-三唑基取代吲唑分子，这些分子在调节蛋白激酶方面具有强效活性。因此，本发明包括口服活性分子和经肠道给药的活性分子，可用于治疗与蛋白激酶信号转导相关的疾病或障碍，且可用较低剂量或血清浓度。
• PYRAZOLO[4,3-D]PYRIMIDINES AS KINASE INHIBITORS
  申请人：ORIGENIS GMBH

  公开号：US20150266882A1

  公开（公告）日：2015-09-24

  The present invention relates to novel compounds of formula (I) that are capable of inhibiting one or more kinases, especially SYK (Spleen Tyrosine Kinase), LRRK2 (Leucine-rich repeat kinase 2) and/or MYLK (Myosin light chain kinase) or mutants thereof. The compounds find applications in the treatment of a variety of diseases. These diseases include autoimmune diseases, inflammatory diseases, bone diseases, metabolic diseases, neurological and neurodegenerative diseases, cancer, cardiovascular diseases, allergies, asthma, alzheimer's disease, parkinson's disease, skin disorders, eye diseases, infectious diseases and hormone-related diseases.

  本发明涉及化合物(I)的新型化合物，能够抑制一个或多个激酶，特别是SYK（脾酪氨酸激酶）、LRRK2（富含亮氨酸重复的激酶2）和/或MYLK（肌球蛋白轻链激酶）或其突变体。这些化合物在治疗多种疾病方面有应用。这些疾病包括自身免疫疾病、炎症性疾病、骨病、代谢性疾病、神经和神经退行性疾病、癌症、心血管疾病、过敏、哮喘、阿尔茨海默病、帕金森病、皮肤疾病、眼病、传染病和激素相关疾病。